By inference—regarding CLEC12A as a marker of myeloid progenitors and their downstream progeny—the presence of CLEC12A on AML blasts and stem cells could indicate a myeloid progenitor/precursor disease, while CLEC12A− AML could correspond to a more immature stem cell disease originating from a cell at the level of the CLEC12A− CMP or upstream. Here, CLEC12A is linked to acute myeloid leukemia.